|
Today's Headlines
FDA has approved a new formulation of Zohydro ER (hydrocodone bitartrate, Zogenix) Extended-Release Capsules, CII, with BeadTek, a formulation technology designed to provide abuse-deterrent properties without changing the release properties of hydrocodone when Zohydro ER is used as intended. » Read about this new technology with abuse-deterrent properties
|
|
FDA approved lisdexamfetamine dimesylate (Vyvanse, Shire) Capsules (CII), the first and only medication for the treatment of moderate to severe binge eating disorder (BED) in adults, shown to significantly reduce the mean number of binge days per week.
» Health risks of BED
|
Continuing Education
This month's CE activity is the last unit of a year-long CPE series, Medication Therapy Management Considerations for Adult Patients with Cardiovascular Disease. Running from February 2014 through January 2015, the series enables pharmacists to earn up to 24 hours of CPE credit with 12 monthly knowledge-based activities from the University of Connecticut School of Pharmacy and Drug Topics.
The goal of this month's activity is to empower pharmacists to engage patients with cardiovascular disease in the practices of self-management.
To read and print the article with TEST QUESTIONS, click here. To proceed to the online exams and earn up to 2 CPE credits, click here to log in with the session code 15DT01-JKF33.
Announcement: Our CE activities have moved to a new learning management system to better serve you. The login to the Online CE Center is
https://web2.uconn.edu/pharmacyce/login.php. All current user registration information has been uploaded for your convenience. Current users do not need to register. To review your registration page to ensure the data is up to date or to register, go to https://web2.uconn.edu/pharmacyce/program_register.php. For a full list of courses, go to http://pharmacy.uconn.edu/academics/ce/drug-topics-and-uconn-ce/
|
|
|
Like
Tweet
